The content on this site is intended for healthcare professionals only
Dr Kolberg speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the phase III LILAC study, looking at ABP 980 with trastuzumab on pathologic complete response in women with HER2 early breast cancer.
He states that central evaluations support clinical equivalence of ABP 980 with trastuzumab and that the study demonstrates the feasibility of including central laboratory review of pathologic complete response rates in a large multi-centre, multinational study.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
